AstraZeneca Pharma (Mid Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
AstraZeneca Pharma India Limited |
|||
|
Price: ₹6,956.35 (+3.02%) | ||
| 52 Week Low: ₹4,785.00 52 Week High: ₹8,139.00 |
|||
| Market Capital: 16,942.94 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: AstraZeneca Pharma Share Price Target For 2025
- 1.1.1: AstraZeneca Pharma Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: AstraZeneca Pharma Share Price Target For 2026
- 1.2.1: AstraZeneca Pharma Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: AstraZeneca Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: AstraZeneca Pharma Brief Company Overview
- 4: AstraZeneca Pharma Financial Performance
- 4.0.1: Is AstraZeneca Pharma A Good Buy For Long Term?
AstraZeneca Pharma, a Mid Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 160.3% returns in 5-year showing 31.2% quarterly revenue growth with 6.9% profit margin, making it a potential Multibagger.
To predict the AstraZeneca Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
AstraZeneca Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of AstraZeneca Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for AstraZeneca Pharma shares in 2025, see the table below.
AstraZeneca Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 7659.95 (+10.11%) | Price Action: 18 Oct 2024 High |
| 2025 Target 2 | 7550.0 (+8.52%) | Price Action: 21 Oct 2024 High |
| 2025 Target 1 | 7460.7 (+7.25%) | Price Action: 01 Nov 2024 Low |
| Current Price | 6956.35 | AstraZeneca Pharma's share price as of 22 Jan 2025 |
| Stop Loss 1 | 6727.65 (-3.29%) | Price Action: 27 Aug 2024 Low |
| Stop Loss 2 | 6656.95 (-4.3%) | Price Action: 06 Feb 2024 Low |
| Stop Loss 3 | 6590.0 (-5.27%) | Price Action: 29 Nov 2024 High |
Short-Term Technical Outlook
Current Technical Position: AstraZeneca Pharma is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹6864.78 serves as the nearest technical reference point.
Historical Returns: 3-month: -8.77% | 6-month: -1.13% | 1-year: +5.13%
AstraZeneca Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of AstraZeneca Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for AstraZeneca Pharma shares in 2026, see the table below.
AstraZeneca Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 10526.51 (+51.32%) | Price Action: Chart |
| 2026 Target 2 | 10330.24 (+48.5%) | Price Action: Chart |
| 2026 Target 1 | 10227.96 (+47.03%) | Fibonacci Extension Level 64.90% |
| Current Price | 6956.35 | AstraZeneca Pharma's share price as of 22 Jan 2025 |
| Stop Loss 1 | 6206.25 (-10.79%) | Price Action: 28 Jun 2024 Low |
| Stop Loss 2 | 6140.0 (-11.74%) | Price Action: 31 May 2024 Low |
| Stop Loss 3 | 6069.7 (-12.75%) | Price Action: 26 Jun 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: AstraZeneca Pharma is currently trading at 64.7% of its 52-week range (₹4785 - ₹8139).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +5.13% | 3-year: +148.77% | 5-year: +160.29%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
AstraZeneca Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹6,956.35 | ||
| 2025 | ₹9,833.50 | +41.36% | ₹9,981.00 |
| 2026 | ₹12,978.04 | +31.97% | ₹13,172.71 |
| 2027 | ₹16,703.04 | +28.7% | ₹16,953.59 |
| 2028 | ₹20,664.81 | +23.71% | ₹20,974.78 |
| 2029 | ₹27,958.04 | +35.29% | ₹28,377.41 |
| 2030 | ₹35,794.73 | +28.03% | ₹36,331.65 |
| 2031 | ₹42,078.14 | +17.55% | ₹42,709.31 |
| 2032 | ₹53,485.55 | +27.11% | ₹54,287.83 |
| 2033 | ₹66,739.38 | +24.78% | ₹67,740.47 |
| 2034 | ₹79,731.54 | +19.46% | ₹80,927.51 |
| 2035 | ₹93,010.10 | +16.65% | ₹94,405.25 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
AstraZeneca Pharma Brief Company Overview
AstraZeneca Pharma India Limited: A Leading Biopharmaceutical Company AstraZeneca Pharma India Limited, established in 1979, is a renowned biopharmaceutical company with operations across India and globally. As a leading manufacturer and marketer of pharmaceuticals,...
AstraZeneca Pharma India caters to the diverse healthcare needs of patients. The company boasts a comprehensive product range, including innovative treatments for cardiovascular diseases, diabetes, respiratory conditions, oncology, renal diseases, and metabolic disorders. Their notable brands include Brilinta, Betaloc, Crestor, and Symbicort, among others. AstraZeneca Pharma India's commitment to research and innovation has earned it a remarkable reputation in the industry. Their diverse product portfolio ensures they cater to a broad spectrum of healthcare needs, making them a trusted partner for patients, healthcare providers, and the industry at large. Key Products: Cardiovascular drugs, diabetes treatments, respiratory medicines, oncology therapeutics, renal products, metabolic treatments, immunology therapies History: Founded in 1979, headquartered in Bengaluru, India Market Presence: Operates in India and internationally Reputation: Recognized for innovation, quality, and commitment to patient care Diverse Product Range: Addresses a wide range of healthcare needs Commitment: To provide innovative therapies for improving patient outcomesAstraZeneca Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 16,942.94 Crore | Market valuation of AstraZeneca Pharma's shares. |
| Revenue (TTM) | 1,387.58 Crore | Total revenue generated by AstraZeneca Pharma over the past twelve months. |
| Net Income (TTM) | +95.86 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +8.81% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +6.9% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+31.2% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.64 | Company's total debt divided by total shareholder equity. |
| Total Debt | 4.59 Crore | Sum of AstraZeneca Pharma's current & long-term financial obligations. |
| Total Cash | 505.56 Crore | Total amount of liquid funds available to AstraZeneca Pharma. |
| Beta | 0.28 | Beta is less than 1 indicating that the AstraZeneca Pharma's price is less volatile than the market. |
Is AstraZeneca Pharma A Good Buy For Long Term?
AstraZeneca Pharma, a mid-cap stock with a market capitalization of ₹16,942.94 crore, shows mixed signals. While its 5-year return of 335.26% is impressive, the recent 3-month return of -10.19% is a concern. A healthy cash balance of ₹505.56 crore (Q1 2024-25) and a low debt of ₹4.59 crore are positive. However, a profit margin of only 6.9% needs improvement. Considering the strong past performance and relatively healthy financials, AstraZeneca Pharma could be considered an average buy for the long term, but further investigation into the reasons for the recent dip is recommended.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
